Interesting regarding Kimberly Clark. Good for the city/area. Not great for Neenah, WI. How many people are actually moving? It actually sounds decent because it's not just 15 C-Suite execs moving but sounds like other more normal people too. I think we know some of their normal consumer brands but they have a massive footprint in offices, doctor's offices, etc etc. My wife is in marketing and works with a number of different clients. You'd be surprised on who spends a lot on marketing, and how much it sometimes quietly (outside of their company) helps them.
In other news:
Good to see more and more life sciences outside of the big boys in the Chicago area getting this. This is a lot of money though these companies tend to use more of their money for actual research, trials, etc than total hiring vs. a "standard" tech company.
Chicago gene therapy startup raises $139M
https://www.bizjournals.com/chicago/...ises-139m.html
Quote:
A Chicago biotech startup led by a team of seasoned life sciences executives raised a major funding round this week from some big-name backers.
Jaguar Gene Therapy, a gene therapy startup helping patients suffering from severe genetic diseases, announced it raised $139 million in Series B funding. The round was co-led by Eli Lilly and Company, and Deerfield Management. Other backers include ARCH Venture Partners, Goldman Sachs and Nolan Capital.
Jaguar is led by the former leadership team at AveXis, an Illinois-based maker of gene replacement therapy for spinal muscular atrophy that was acquired by Novartis in 2018 for nearly $9 billion. Jaguar is led by Joe Nolan, a former AveXis executive who also held leadership roles at Lundbeck and Abbott Laboratories.
Founded in 2019, Jaguar is creating gene therapy treatments for patients battling genetic diseases, such as galactosemia, autism spectrum disorder, Type 1 diabetes and Bardet-Biedl syndrome. The startup said it will use the funding to advance the initial pre-clinical pipeline of its therapies.
Jaguar, headquartered in Lake Forest, is among the breakout biotech startups in Chicago's burgeoning life sciences scene. After decades of falling behind other U.S. cities in venture capital raised and access to lab space, the city's biotech ecosystem appears to be gaining momentum. Hundreds of thousands of square feet of lab space is currently under construction across several buildings in Chicago, including Trammell Crow's Fulton Labs project in the West Loop and Sterling Bay's Prysm Life Sciences initiative in Lincoln Park.
|